A phase I, open-label, randomized, crossover study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in a modified release formulation (MR2) and compare the bioavailability between MR2 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects.

Trial Profile

A phase I, open-label, randomized, crossover study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in a modified release formulation (MR2) and compare the bioavailability between MR2 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Prostate cancer; Systemic mastocytosis
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 25 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top